Livmarli now approved in US for PFIC patients 1 year and older
The U.S. Food and Drug Administration (FDA) has approved a label expansion for Livmarli (maralixibat) that allows the medication to be used in patients with…
Lindsey Shapiro, PhD, Science Writer — 
Articles by Lindsey Shapiro
PSC may increase ulcerative colitis risk, but not Crohn’s disease
Genetic variations that predispose people toward developing primary sclerosing cholangitis (PSC) are significantly associated with a higher risk of ulcerative colitis, a primary type…
More studies support use of CM-101 antibody therapy now in PSC trial
High levels of CCL24, the protein targeted by Chemomab Therapeutics’ investigational antibody-based therapy CM-101, are associated with biological pathways contributing to the progression of…
Volixibat shows early promise for reducing PBC itching, fatigue: Data
Daily treatment with Mirum Pharmaceuticals’ oral candidate volixibat significantly reduced itching — medically known as pruritus — and fatigue for adults with primary…
Targeting SEMA3A protein could help slow MASLD: Study
A protein called semaphorin-3A (SEMA3A) may be a key player in the early cellular mechanisms that cause fat to accumulate in the livers of people…
Imdusiran plus immunotherapy may help in chronic hepatitis B
In ongoing proof-of-concept Phase 2a trials, Arbutus BioPharma’s imdusiran is showing an ability to possibly eliminate chronic hepatitis B infections when used in…
Blood levels of GDF15 protein may help in liver cancer risk of MASLD
High blood levels of the growth differentiation factor 15 (GDF15) protein are associated with an elevated risk of liver cancer and other liver-related complications among…
BJT-778 antibody therapy shows early promise in Hep D trial
Bluejay Therapeutics’ investigational antibody therapy BJT-778 appears to safely and effectively lower levels of the hepatitis D virus (HDV) and markers of liver inflammation…
Tobevibart, elebsiran can suppress hepatitis D virus: Phase 2 data
Vir Biotechnology’s investigational therapy tobevibart, used alone or in combination with another company candidate called elebsiran, can reduce hepatitis D virus (HDV) levels and…
US doctors prescribe Rezdiffra, note concern about patient costs
Physicians from the GI Alliance, the largest physician-led network of gastroenterologists in the U.S., are now actively prescribing Rezdiffra (resmetirom) to eligible people…